| Entry |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Rilpivirine (JAN/USAN/INN); Rekambys (TN) | ||||||||||
| Formula | C22H18N6 | ||||||||||
| Exact mass | 366.1593 | ||||||||||
| Mol weight | 366.4185 | ||||||||||
| Structure |  | ||||||||||
| Simcomp | |||||||||||
| Class | Antiviral DG01889 Non-nucleoside reverse transcriptase inhibitor (NNRTI) DG03107 Anti-HIV agent DG01656 HIV reverse transcriptase inhibitor Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate | ||||||||||
| Remark |
| ||||||||||
| Efficacy | Antiviral, Reverse transcriptase inhibitor | ||||||||||
| Target | HIV-1 reverse transcriptase [KO:K24802] | ||||||||||
| Pathway |
| ||||||||||
| Metabolism | Enzyme: CYP3A [HSA:1576 1577 1551] | ||||||||||
| Interaction | |||||||||||
| Structure map |
| ||||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] J ANTIINFECTIVES FOR SYSTEMIC USE J05 ANTIVIRALS FOR SYSTEMIC USE J05A DIRECT ACTING ANTIVIRALS J05AG Non-nucleoside reverse transcriptase inhibitors J05AG05 Rilpivirine D09720 Rilpivirine (JAN/USAN/INN) <JP> Therapeutic category of drugs in Japan [BR:br08301] 6 Agents against pathologic organisms and parasites 62 Chemotherapeutics 625 Antivirals 6250 Antivirals D09720 Rilpivirine (JAN/USAN/INN) Drug groups [BR:br08330] Antiviral DG01889 Non-nucleoside reverse transcriptase inhibitor (NNRTI) DG00663 Rilpivirine D09720 Rilpivirine DG03107 Anti-HIV agent DG01656 HIV reverse transcriptase inhibitor DG00663 Rilpivirine D09720 Rilpivirine Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG00663 Rilpivirine D09720 Rilpivirine Drug classes [BR:br08332] Antiviral DG03107 Anti-HIV agent D09720 Rilpivirine Antimicrobials [BR:br08307] Antivirals Genome replication inhibitor HIV reverse transcriptase inhibitor D09720 Rilpivirine (JAN/USAN/INN) <JP> New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D09720 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D09720 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D09720 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D09720 Drug groups [BR:br08330] Antiviral DG01889 Non-nucleoside reverse transcriptase inhibitor (NNRTI) DG00663 Rilpivirine DG03107 Anti-HIV agent DG01656 HIV reverse transcriptase inhibitor DG00663 Rilpivirine Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate DG00663 Rilpivirine Antimicrobials abbreviations [BR:br08327] Antivirals Genome replication inhibitor HIV reverse transcriptase inhibitor DG00663 Rilpivirine | ||||||||||
| Other DBs |
| ||||||||||
| KCF data | ATOM 28 1 C8y C 22.1900 -21.7700 2 C8x C 22.1900 -23.1700 3 C8y C 23.4024 -23.8700 4 C8y C 24.6149 -23.1700 5 C8y C 24.6149 -21.7700 6 C8x C 23.4024 -21.0700 7 N1b N 25.8460 -23.8810 8 C8y C 27.0512 -23.1853 9 N5x N 28.2335 -23.8681 10 C8y C 29.4460 -23.1683 11 N5x N 29.4462 -21.7683 12 C8x C 28.2638 -21.0855 13 C8x C 27.0513 -21.7853 14 N1b N 30.6770 -23.8793 15 C8y C 31.8807 -23.1846 16 C8x C 33.0637 -23.8678 17 C8x C 34.2762 -23.1681 18 C8y C 34.2765 -21.7681 19 C8x C 33.0935 -21.0848 20 C8x C 31.8810 -21.7846 21 C1a C 25.8460 -21.0590 22 C3b C 35.5057 -21.0585 23 N3a N 36.7181 -20.3585 24 C2b C 20.9776 -21.0700 25 C2b C 19.7821 -21.7604 26 C3b C 18.5947 -21.0749 27 N3a N 17.3823 -20.3749 28 C1a C 23.4024 -25.2698 BOND 30 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 4 7 1 8 7 8 1 9 8 9 1 10 9 10 2 11 10 11 1 12 11 12 2 13 12 13 1 14 8 13 2 15 10 14 1 16 14 15 1 17 15 16 1 18 16 17 2 19 17 18 1 20 18 19 2 21 19 20 1 22 15 20 2 23 5 21 1 24 18 22 1 25 22 23 3 26 1 24 1 27 24 25 2 28 25 26 1 29 26 27 3 30 3 28 1 |